Enter at least 4 characters

1 results showing for: 'meningococcal (groups a, c, y and w-135) conjugate vaccine'

Meningococcal (groups A, C, Y and W-135) conjugate vaccine    Medsafe Data Sheets   New Zealand Formulary.   Hospital Medicines List.   PDF Schedule - Refer from page 312.
  • Inj 10 mcg of each meningococcal polysaccharide conjugated to a total of approximately 55 mcg of tetanus toxoid carrier per 0.5 ml vial - Only on a prescription - No patient co-payment payable
    • Brand Fully subsidised brand. MenQuadfi
    • Pharmacode2649012
    • Subsidy $0.00
    • Measure / Qty per 1
    1. Any of the following:

      1. Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or

      2. One dose for close contacts of meningococcal cases of any group; or

      3. One dose for person who has previously had meningococcal disease of any group; or

      4. A maximum of two doses for bone marrow transplant patients; or

      5. A maximum of two doses for person pre- and post-immunosuppression*; or

    2. Both:

      1. Person is aged between 13 and 25 years, inclusive; and

      2. Either:

        1. One dose for individuals who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, Youth Justice residences, or prisons; or

        2. One dose for individuals who turn 13 years of age while living in boarding school hostels.

    3. Contractors will be entitled to claim payment from the Funder for the supply of Meningococcal A, C, Y and W-135 vaccine to patients eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Meningococcal A, C, Y and W-135 vaccine listed in the Pharmaceutical Schedule.

    4. Contractors may only claim for patient populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraphs A-B above.

    Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly. *Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

  • Inj 5 mcg of each meningococcal polysaccharide conjugated to a total of approximately 44 mcg of tetanus toxoid carrier per 0.5 ml vial [Xpharm]
    • Brand Fully subsidised brand. Nimenrix
    • Pharmacode2506971
    • Subsidy $0.00
    • Measure / Qty per 1
    1. Both:

      1. The child is under 12 months of age; and

      2. Any of the following:

        1. A maximum of three doses (dependant on age at first dose) for patients pre- and post- splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post- solid organ transplant; or

        2. A maximum of three doses (dependant on age at first dose) for close contacts of meningococcal cases of any group; or

        3. A maximum of three doses (dependant on age at first dose) for child who has previously had meningococcal disease of any group; or

        4. A maximum of three doses (dependant on age at first dose) for bone marrow transplant patients; or

        5. A maximum of three doses (dependant on age at first dose) for child pre- and post-immunosuppression*.

    Note: infants from 6 weeks to less than 6 months of age require a 2+1 schedule, infants from 6 months to less than 12 months of age require a 1+1 schedule. Refer to the Immunisation Handbook for recommended booster schedules with meningococcal ACWY vaccine. *Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

  • Rectangle page icon symoblising a PDF. PDF
  • A tick icon. Fully subsidised
  • An oval with the number 29 in it. Unapproved medicine under Section 29
  • An asterisk symbol. 3 or 6 months should be dispensed at once
  • Two duplicate pages icon. Click to copy
  • A triangle symbol. Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.
  • OP Original pack
  • Sole Subsidised Supply